These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24383843)

  • 1. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
    Deininger MW; Kopecky KJ; Radich JP; Kamel-Reid S; Stock W; Paietta E; Emanuel PD; Tallman M; Wadleigh M; Larson RA; Lipton JH; Slovak ML; Appelbaum FR; Druker BJ
    Br J Haematol; 2014 Jan; 164(2):223-32. PubMed ID: 24383843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
    Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
    Proetel U; Pletsch N; Lauseker M; Müller MC; Hanfstein B; Krause SW; Kalmanti L; Schreiber A; Heim D; Baerlocher GM; Hofmann WK; Lange E; Einsele H; Wernli M; Kremers S; Schlag R; Müller L; Hänel M; Link H; Hertenstein B; Pfirrman M; Hochhaus A; Hasford J; Hehlmann R; Saußele S; ;
    Ann Hematol; 2014 Jul; 93(7):1167-76. PubMed ID: 24658964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
    Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
    Kim SH; Menon H; Jootar S; Saikia T; Kwak JY; Sohn SK; Park JS; Jeong SH; Kim HJ; Kim YK; Oh SJ; Kim H; Zang DY; Chung JS; Shin HJ; Do YR; Kim JA; Kim DY; Choi CW; Park S; Park HL; Lee GY; Cho DJ; Shin JS; Kim DW
    Haematologica; 2014 Jul; 99(7):1191-6. PubMed ID: 24705186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
    Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
    Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
    Radich JP; Kopecky KJ; Appelbaum FR; Kamel-Reid S; Stock W; Malnassy G; Paietta E; Wadleigh M; Larson RA; Emanuel P; Tallman M; Lipton J; Turner AR; Deininger M; Druker BJ
    Blood; 2012 Nov; 120(19):3898-905. PubMed ID: 22915637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
    Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
    Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
    Baccarani M; Druker BJ; Branford S; Kim DW; Pane F; Mongay L; Mone M; Ortmann CE; Kantarjian HM; Radich JP; Hughes TP; Cortes JE; Guilhot F
    Int J Hematol; 2014; 99(5):616-24. PubMed ID: 24658916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
    N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
    Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
    Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
    Falchi L; Kantarjian HM; Wang X; Verma D; Quintás-Cardama A; O'Brien S; Jabbour EJ; Ravandi-Kashani F; Borthakur G; Garcia-Manero G; Verstovsek S; Burger JA; Luthra R; Cortes JE
    Am J Hematol; 2013 Dec; 88(12):1024-9. PubMed ID: 23913852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
    Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
    Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
    Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
    Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
    PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
    N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
    Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G
    Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
    Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
    J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.